Hypertension

High blood pressure increases a patient's risk of heart attack, stroke and other diseases. Most people with hypertension have no symptoms. The Centers for Disease Control and Prevention (CDC) says nearly half of U.S. adults have hypertension, or high blood pressure, and only about 1 in 4 of those individuals has their hypertension under control. The World Health Organization (WHO) expects the epidemic of hypertension world-wide will exceed 1.56 billion people by 2025. Major efforts are underway to better control this primary risk factor through screenings, medication and invasive procedures such as renal denervation in severely uncontrolled patients.

FDA approves new drugs for pulmonary arterial hypertension from Johnson & Johnson, Merck
Cardiologists now have two more tools to help them combat PAH, a rare vascular condition that often leads to heart failure.
FDA approves new hypertension drug months after Idorsia reacquired rights for $343M
Aprocitentan, sold under the brand name Tryvio, is approved for patients with high blood pressure who are already taking other antihypertensive drugs.
World’s first patient treated with new implantable device for pulmonary hypertension
The procedure, performed on Feb. 14, was part of an early feasibility trial developed with help from the FDA.
Flexitarian diet, a plant-based option that includes small amounts of meat, linked to key cardiovascular benefits
The study, designed to compare flexitarians with vegans and omnivores, focused on young and middle-aged adults in good health who had been following the same diet for at least one full year.
Salt substitutes reduce hypertension risk by up to 40%
Many patients do not want to limit their salt intake, even when a doctor tells them the numerous health benefits. Salt substitutes may represent another way forward.

Medtronic Begins Renal Denervation Study for High Blood Pressure Patients Prescribed Anti-Hypertensive Medication

Medtronic announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system in patients with high blood pressure (hypertension) who are already prescribed anti-hypertension medications.

November 8, 2018

Renal denervation linked to significant drops in blood pressure

Two late-breaking clinical trials presented May 23 at EuroPCR in London demonstrated the ability of renal denervation to significantly lower patients’ blood pressures, regardless of whether they were taking antihypertensive medications.

May 23, 2018

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

DUBLIN — April 9, 2018 — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension).

April 9, 2018

Hypertension

FDA approves new drugs for pulmonary arterial hypertension from Johnson & Johnson, Merck

FDA approves new hypertension drug months after Idorsia reacquired rights for $343M

World’s first patient treated with new implantable device for pulmonary hypertension

Flexitarian diet, a plant-based option that includes small amounts of meat, linked to key cardiovascular benefits

Salt substitutes reduce hypertension risk by up to 40%